Determination of the amino acid residues in substance P conferring selectivity and specificity for the rat neurokinin receptors

MA Cascieri, RR Huang, TM Fong, AH Cheung, S Sadowski, E Ber and CD Strader

Department of Molecular Pharmacology and Biochemistry, Merck Research Laboratories, Rahway, New Jersey 07065.

We have measured the affinity of various analogs and fragments of the tachykinin substance P for the cloned rat NK1, NK2, and NK3 receptors heterologously expressed in Chinese hamster ovary cells. The hydrophobic carboxyl-terminal pentapeptide sequence substance P-(7-11) binds with similar affinity (2-20 microM) to all three receptors. Our data suggest that addition of one to three amino-terminal residues to this sequence results in the optimization of its interaction within the binding pocket of the NK1 receptor. The addition of Pro-Gln-Gln to the carboxyl-terminal pentapeptide sequence increases affinity for the NK1 receptor, either by providing additional binding interactions or by modifying the conformation of the carboxyl-terminal sequence. This latter hypothesis is supported by the observation that physalaemin and phyllomedusin, which also contain a proline residue in the position analogous to the proline residue 4 of substance P, are also selective for NK1 receptors. Tachykinins that lack this proline have no higher affinity for NK1 than [pGlu] substance P-(6-11). Conversely, addition of Pro-Gln-Gln to the carboxyl-terminal pentapeptide sequence is unfavorable for NK2 and NK3 receptor binding. Preliminary data suggest that tachykinins with high affinity (Kd less than 500 nM) for NK2 receptors contain an aspartate residue in the position analogous to residue 5 of substance P, suggesting that an ionic interaction with the receptor may contribute binding energy. Further experiments will be required to determine the structural determinants of the NK1, NK2, and NK3 receptors responsible for these binding properties.

Volume 41, Issue 6, pp. 1096-1099, 06/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				I. Langer, I. G. Tikhonova, M.-A. Travers, E. Archer-Lahlou, C. Escrieut, B. Maigret, and D. Fourmy Evidence That Interspecies Polymorphism in the Human and Rat Cholecystokinin Receptor-2 Affects Structure of the Binding Site for the Endogenous Agonist Cholecystokinin J. Biol. Chem., June 10, 2005; 280(23): 22198 - 22204. [Abstract] [Full Text] [PDF]

				A. Dike and S. M. Cowsik Membrane-Induced Structure of Scyliorhinin I: A Dual NK1/NK2 Agonist Biophys. J., May 1, 2005; 88(5): 3592 - 3600. [Abstract] [Full Text] [PDF]

				I. R. Chandrashekar and S. M. Cowsik Three-Dimensional Structure of the Mammalian Tachykinin Peptide Neurokinin A Bound to Lipid Micelles Biophys. J., December 1, 2003; 85(6): 4002 - 4011. [Abstract] [Full Text] [PDF]

				R. C. R. Grace, I. R. Chandrashekar, and S. M. Cowsik Solution Structure of the Tachykinin Peptide Eledoisin Biophys. J., January 1, 2003; 84(1): 655 - 664. [Abstract] [Full Text] [PDF]

				C. Severini, G. Improta, G. Falconieri-Erspamer, S. Salvadori, and V. Erspamer The Tachykinin Peptide Family Pharmacol. Rev., June 1, 2002; 54(2): 285 - 322. [Abstract] [Full Text] [PDF]

				I. Marriott and K. L. Bost IL-4 and IFN-{gamma} Up-Regulate Substance P Receptor Expression in Murine Peritoneal Macrophages J. Immunol., July 1, 2000; 165(1): 182 - 191. [Abstract] [Full Text] [PDF]

				S.-E. W. Huskey, D. Luffer-Atlas, B. J. Dean, E. M. McGowan, W. P. Feeney, and S.-H. L. Chiu Substance P Receptor Antagonist I: Conversion of Phosphoramidate Prodrug after i.v. Administration to Rats and Dogs Drug Metab. Dispos., November 1, 1999; 27(11): 1367 - 1373. [Abstract] [Full Text]

				S. Sagan, J.-C. Beaujouan, Y. Torrens, M. Saffroy, G. Chassaing, J. Glowinski, and S. Lavielle High Affinity Binding of [3H]Propionyl-[Met(O2)11]Substance P(7-11), a Tritiated Septide-Like Peptide, in Chinese Hamster Ovary Cells Expressing Human Neurokinin-1 Receptors and in Rat Submandibular Glands Mol. Pharmacol., July 1, 1997; 52(1): 120 - 127. [Abstract] [Full Text]

				R. A. Velázquez, K. F. Kitto, and A. A. Larson J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1231 - 1237. [Abstract] [Full Text]

				Y. Tian, L.-H. Wu, D. L. Oxender, and F.-Z. Chung The Unpredicted High Affinities of a Large Number of Naturally Occurring Tachykinins for Chimeric NK1/NK3 Receptors Suggest a Role for an Inhibitory Domain in Determining Receptor Specificity J. Biol. Chem., August 23, 1996; 271(34): 20250 - 20257. [Abstract] [Full Text] [PDF]